Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00279617 |
Recruitment Status :
Completed
First Posted : January 19, 2006
Last Update Posted : December 13, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Panic Disorder | Drug: levetiracetam | Phase 3 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 15 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks |
Study Start Date : | January 2006 |
Actual Primary Completion Date : | February 2009 |
Actual Study Completion Date : | March 2009 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Levetricetam
open label treatment
|
Drug: levetiracetam
open label levetricetam
Other Name: Keppra |
- Hamilton Anxiety scale (HAM-A) [ Time Frame: each visit ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Outpatient subjects age 18 years or older.
- Subjects must meet DSM-IV-TR criteria for panic disorder with or without agoraphobia.
- Subjects must experience a minimum of one panic attack per week over the month preceding the study.
- Subjects must be fluent in English.
- Subjects must be able to provide and understand written informed consent.
Exclusion Criteria:
- Subjects unable to provide and understand written informed consent.
- Subjects previously treated with levetiracetam.
- Subjects who meet DVM-IV-TR criteria for current diagnosis of mood, psychotic or substance use disorder.
- Subjects who have acute or unstable medical illness.
- Subjects with a history of seizures or structural brain damage from trauma.
- Subjects currently receiving successful treatment for panic disorder (i.e., subjects will not have medications discontinued to participate in the study if they are effective in the treatment of their panic attacks).
- Subjects susceptible to lactate infusions.
- Female subjects who are pregnant or lactating.
- Female subjects who, if fertile, are not using medically acceptable and reliable method of contraception.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00279617
United States, Ohio | |
University of Cincinnati Medical Center | |
Cincinnati, Ohio, United States, 45267-0559 |
Principal Investigator: | Paul Keck, MD | University of Cincinnati |
Responsible Party: | Lindner Center of HOPE |
ClinicalTrials.gov Identifier: | NCT00279617 |
Other Study ID Numbers: |
2-Miefert |
First Posted: | January 19, 2006 Key Record Dates |
Last Update Posted: | December 13, 2011 |
Last Verified: | December 2011 |
Panic Disorder Anxiety Disorders Mental Disorders |
Levetiracetam Anticonvulsants Nootropic Agents |